MA33097B1 - Anticorps contre la protéine tweak humaine et leurs utilisations - Google Patents

Anticorps contre la protéine tweak humaine et leurs utilisations

Info

Publication number
MA33097B1
MA33097B1 MA34141A MA34141A MA33097B1 MA 33097 B1 MA33097 B1 MA 33097B1 MA 34141 A MA34141 A MA 34141A MA 34141 A MA34141 A MA 34141A MA 33097 B1 MA33097 B1 MA 33097B1
Authority
MA
Morocco
Prior art keywords
antibodies against
against human
human tweak
tweak protein
protein
Prior art date
Application number
MA34141A
Other languages
Arabic (ar)
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33097B1 publication Critical patent/MA33097B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA34141A 2009-04-02 2010-03-30 Anticorps contre la protéine tweak humaine et leurs utilisations MA33097B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02
PCT/EP2010/002009 WO2010115555A2 (fr) 2009-04-02 2010-03-30 Anticorps contre la protéine tweak humaine et leur utilisation

Publications (1)

Publication Number Publication Date
MA33097B1 true MA33097B1 (fr) 2012-03-01

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34141A MA33097B1 (fr) 2009-04-02 2010-03-30 Anticorps contre la protéine tweak humaine et leurs utilisations

Country Status (23)

Country Link
US (3) US8093006B2 (fr)
EP (2) EP2414398A2 (fr)
JP (1) JP5596777B2 (fr)
KR (1) KR101344611B1 (fr)
CN (1) CN102369219A (fr)
AR (1) AR076020A1 (fr)
AU (1) AU2010233997A1 (fr)
BR (1) BRPI1014867A2 (fr)
CA (1) CA2756245A1 (fr)
CL (1) CL2011002452A1 (fr)
CO (1) CO6362025A2 (fr)
CR (1) CR20110462A (fr)
EC (1) ECSP11011362A (fr)
IL (1) IL214355A0 (fr)
MA (1) MA33097B1 (fr)
MX (1) MX2011010117A (fr)
NZ (1) NZ594347A (fr)
PE (1) PE20120577A1 (fr)
RU (1) RU2011143903A (fr)
SG (2) SG10201404107SA (fr)
TW (1) TWI423815B (fr)
UA (1) UA105520C2 (fr)
WO (1) WO2010115555A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
EP2683740B1 (fr) 2011-03-10 2018-07-04 Omeros Corporation Génération d'anticorps monoclonaux anti-fn14 par développement accéléré d'anticorps ex-vivo
EP2834273B1 (fr) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Anticorps bispécifiques contre la protéine tweak humaine et il17 humain et leurs utilisations
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
IL282650B2 (en) * 2018-10-31 2024-09-01 Astellas Pharma Inc Anti-human fn14 antibody
WO2025005938A1 (fr) * 2023-06-26 2025-01-02 Memorial Sloan-Kettering Cancer Center Anticorps et fragments de liaison à l'antigène de ceux-ci se liant à des récepteurs chimériques et leurs utilisations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
CN101024831A (zh) 1996-08-07 2007-08-29 拜奥根Idec马萨诸塞公司 肿瘤坏死因子相关配基
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
WO1998035061A2 (fr) 1997-02-12 1998-08-13 Abbott Laboratories Element de la famille tnf utilise pour le traitement et le diagnostic d'une maladie
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP1021542B1 (fr) 1997-10-10 2009-03-04 Genentech, Inc. Ligand apo-3
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
AU2937300A (en) 1999-03-04 2000-09-21 Vision Sciences, Inc. Image sensor's unit cell with individually controllable electronic shutter circuit
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
WO2001030374A1 (fr) 1999-10-22 2001-05-03 The University Of Pittsburgh Proteines cellulaires ameliorant la prise de greffe de cellules souches et utilisations de ces proteines
AU8028400A (en) 1999-10-22 2001-05-08 Scimed Life Systems, Inc. Guided injection device
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CA2887716C (fr) 2002-04-09 2017-01-24 Biogen Idec Ma Inc. Procede pour traiter les etats lies a tweak
WO2006052926A2 (fr) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
BRPI0608012A2 (pt) 2005-03-07 2009-11-03 Genentech Inc método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
CA2607697C (fr) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
WO2006130429A2 (fr) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Traitement du cancer
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
US20120207750A1 (en) 2012-08-16
WO2010115555A3 (fr) 2011-01-06
MX2011010117A (es) 2011-10-14
KR101344611B1 (ko) 2013-12-30
US8883976B2 (en) 2014-11-11
CO6362025A2 (es) 2012-01-20
UA105520C2 (uk) 2014-05-26
JP2012521771A (ja) 2012-09-20
CA2756245A1 (fr) 2010-10-14
AU2010233997A1 (en) 2011-08-18
NZ594347A (en) 2012-09-28
IL214355A0 (en) 2011-09-27
CL2011002452A1 (es) 2012-03-23
CR20110462A (es) 2011-09-21
WO2010115555A2 (fr) 2010-10-14
TW201039847A (en) 2010-11-16
US20100255008A1 (en) 2010-10-07
PE20120577A1 (es) 2012-05-23
EP2597104A1 (fr) 2013-05-29
SG175005A1 (en) 2011-11-28
AR076020A1 (es) 2011-05-11
BRPI1014867A2 (pt) 2016-04-12
US8852887B2 (en) 2014-10-07
US8093006B2 (en) 2012-01-10
RU2011143903A (ru) 2013-05-10
US20120083015A1 (en) 2012-04-05
SG10201404107SA (en) 2014-10-30
KR20110122868A (ko) 2011-11-11
TWI423815B (zh) 2014-01-21
ECSP11011362A (es) 2011-10-31
JP5596777B2 (ja) 2014-09-24
CN102369219A (zh) 2012-03-07
EP2414398A2 (fr) 2012-02-08

Similar Documents

Publication Publication Date Title
MA33097B1 (fr) Anticorps contre la protéine tweak humaine et leurs utilisations
FR25C1055I1 (fr) Anticorps anti-peptide beta-amyloide n3pglu et leurs utilisations
EP2542221A4 (fr) Formulations concentrées de protéine et leurs utilisations
EP2279210A4 (fr) Peptides de ciblage lysosomial et leurs utilisations
EP2318429A4 (fr) Fragments peptidiques de prominine-1 et leurs utilisations
EP2635605A4 (fr) Anticorps anti-her3 et compositions
EP2593469A4 (fr) Protéines et polypeptides modifiés et leurs utilisations
EP2068887A4 (fr) Anticorps sp35 et leurs utilisations
FR17C1022I2 (fr) Anticorps humains à grande affinité contre pcsk9
EP2579893A4 (fr) Constructions glycopeptidiques multivalentes et leurs utilisations
EP2533810A4 (fr) Anticorps anti-cd20 et utilisations de ceux-ci
EP2247305A4 (fr) Anticorps stabilisés contre l'angiopoïétine-2 et leurs utilisations
EP2391714A4 (fr) Procédés de ligature et utilisations associées
EP2158221A4 (fr) Di-anticorps covalents et leurs utilisations
EP2318029A4 (fr) Polypeptides g-csf bovins modifiés et leurs utilisations
EP2605789A4 (fr) Polypeptides de relaxine modifiés et leurs utilisations
EP2760889A4 (fr) Anticorps contre tl1a et leurs utilisations
EP2627349A4 (fr) Gènes de l'obésité, leurs protéines et leurs utilisations
EP2331573A4 (fr) Anticorps contre l hépatite c et leurs utilisations
EP2686350A4 (fr) Anticorps du facteur tissulaire humain et utilisations correspondantes
IT1392520B1 (it) Struttura di calzatura impermeabile e traspirante
EP2251006A4 (fr) Microparticules et leurs compositions pharmaceutiques
EP2483292A4 (fr) Polypeptides lovd variants et leurs utilisations
EP2285832A4 (fr) Anticorps et leurs procédés de préparation
EP2632952A4 (fr) Anticorps anti-sod1 et utilisations de ceux-ci